Treatment with the drug olaparib significantly reduced the risk of disease progression or death from metastatic pancreatic cancer, according to findings from the recently completed, international, phase-III POLO (Pancreas ...
Jun 3, 2019
0
3
A research team co-led by UCLA investigators has shown that an immunotherapy drug combination can be an effective second-line therapy for patients with an aggressive and deadly type of melanoma that is resistant to the widely ...
Aug 17, 2023
0
38
The Response Evaluation Criteria In Solid Tumors (RECIST), used in many clinical trials to evaluate changes in tumor burden over time, classify objective tumor response into one of four categories (complete or partial response, ...
Jun 3, 2023
0
4
Josep Tabernero, Director of the Vall d'Hebron Institute of Oncology (VHIO), presented data from the international phase III SUNLIGHT study during an Oral Abstract Session at this week's American Society of Clinical Oncology's ...
Jan 23, 2023
0
8
Indiana University School of Medicine researchers Milan Radovich, Ph.D., and Bryan Schneider, MD, have discovered that the presence of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in the plasma of women's ...
Jul 9, 2020
0
3
Two studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated clinical benefit from novel targeted therapies, which may offer new treatment options for patients with metastatic hormone receptor-positive ...
Dec 6, 2023
0
1
A recent study, published in Nature Communications, focuses on the interaction between free fatty acids (FFAs) and GPR84, a G protein-coupled receptor (GPCR).
Nov 22, 2023
0
0
Starting in 2016, a two-year partnership between the North Carolina Chapter of the American College of Cardiology (NCACC) and the North Carolina Association of Free and Charitable Clinics (NCAFCC) provided free lipid lowering ...
Jan 17, 2020
0
2
(HealthDay)—For patients with advanced squamous non-small cell lung cancer (sq- NSCLC), adding tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS), according to a study ...
Apr 5, 2021
0
2
Adding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) time for patients with advanced biliary tract cancers, although it may provide a benefit ...
Jan 20, 2023
0
4
